These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37766429)

  • 1. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
    Wong B; Bergeron A; Maznyi G; Ng K; Jirovec A; Birdi HK; Serrano D; Spinelli M; Thomson M; Taha Z; Alwithenani A; Chen A; Lorimer I; Vanderhyden B; Arulanandam R; Diallo JS
    Mol Ther; 2023 Nov; 31(11):3176-3192. PubMed ID: 37766429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
    Kurmasheva N; Said A; Wong B; Kinderman P; Han X; Rahimic AHF; Kress A; Carter-Timofte ME; Holm E; van der Horst D; Kollmann CF; Liu Z; Wang C; Hoang HD; Kovalenko E; Chrysopoulou M; Twayana KS; Ottosen RN; Svenningsen EB; Begnini F; Kiib AE; Kromm FEH; Weiss HJ; Di Carlo D; Muscolini M; Higgins M; van der Heijden M; Arulanandam R; Bardoul A; Tong T; Ozsvar A; Hou WH; Schack VR; Holm CK; Zheng Y; Ruzek M; Kalucka J; de la Vega L; Elgaher WAM; Korshoej AR; Lin R; Hiscott J; Poulsen TB; O'Neill LA; Roy DG; Rinschen MM; van Montfoort N; Diallo JS; Farin HF; Alain T; Olagnier D
    Nat Commun; 2024 May; 15(1):4096. PubMed ID: 38750019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
    Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
    EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
    Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
    Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
    Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
    BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy.
    Alwithenani A; Arulanandam R; Wong B; Spinelli MM; Chen A; Maznyi G; Gilchrist VH; Alain T; Diallo JS
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
    Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Thiruvengadam SK; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
    Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
    Alluqmani N; Jirovec A; Taha Z; Varette O; Chen A; Serrano D; Maznyi G; Khan S; Forbes NE; Arulanandam R; Auer RC; Diallo JS
    Front Immunol; 2022; 13():1032356. PubMed ID: 36532027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
    Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
    Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
    Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
    Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
    Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
    Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
    Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
    Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
    Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
    Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.